might have been effective. Only Sprung et al. (1) have evaluated the role and impact of a CEC in an international sepsis trial (INTERSEPT).
The multinational, phase 3 PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) trial evaluating drotrecogin alfa (activated), a recombinant human activated protein C, for the treatment of severe sepsis is the first sepsis trial to demonstrate a significant reduction in mortality rate (10) . In PROWESS, the CEC was formed in the event the trial was negative, to evaluate the quality of the PROWESS trial in terms of compliance of the protocol, interpretation of microbiological data, frequency of forgoing lifesustaining therapies, and role of underlying diseases. Although the PROWESS trial was positive, it was still of interest for the CEC to evaluate the appropriateness of the patient population with respect to entry and exclusion criteria, the severity of underlying disorders, the microbiological data, the primary site of infection, the adequacy of anti-infective therapy, the extent of life support measures, and the cause of death as well as conduct a post hoc analysis of the effects of a protocol amendment. We report here the methodology of the PROWESS CEC and the effect of drotrecogin alfa (activated) in the subgroups of PROWESS established by CEC analyses-the optimal cohort, the site of infection, the patients receiving adequate anti-infective therapy, and the patients with a significant underlying disorder on study entry.
MATERIALS AND METHODS
Overall Trial. PROWESS was a randomized, double-blind, placebo-controlled trial evaluating the efficacy of drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, IN) in adult patients with severe sepsis (10) .
To prevent confusion regarding the enrollment of patients with certain kinds of bleeding risks (e.g., cirrhosis), as well as patients with substantial comorbidities (e.g., metastatic cancer), an amendment was developed early in the PROWESS trial whose primary purpose was to clarify the exclusion criteria. In addition, oxygenation and acidosis organ failure entry criteria were clarified to ensure appropriate enrollment. Original and amended entry and exclusion criteria are presented in Appendix 1. During the time period the amendment changes were being finalized and appropriate regulatory and ethical review board approval was being sought, approximately one third of the patients were enrolled under the original protocol. The CEC evaluated all patients enrolled in PROWESS, including those enrolled under the original protocol, using the amended inclusion/exclusion criteria.
Clinical Evaluation Committee Review. The CEC, composed of ten investigators in the PROWESS trial, performed a blinded, critical, integrated review of case report form (CRF) data from complicated sepsis patients and made assessments. This was a planned analysis that was conducted concurrently with but independent of the PROWESS trial, and all CEC reviews of patient data were completed before unblinding of the PROWESS outcome data.
All members of the CEC were selected by the sponsor of the trial and the chairman of the CEC from the PROWESS trial investigators based on their expertise in infectious disease, critical care, or surgery in the United States and Europe. The members represented physicians in diverse medical cultures who have considerable experience in the practice of medicine to adequately perform a critical analysis of the study. A critical care medicine specialist senior physician (JFD) served as the chairman of the CEC. An infectious disease expert senior physician (DM) served as the co-chairman of the CEC. The role of the chairman/co-chairman was to control overall management of the CEC, to check all charts previously reviewed by two CEC members, and to reconcile any discrepancies raised in the review process. The remaining eight members of the CEC served as reviewers of CRF data.
No members of the CEC were permitted to review CRF data on a patient from their own investigative site. The CEC evaluated all case report forms of the intention-to-treat (ITT) population. For evaluation of the CRFs, patients were randomly assigned to two reviewers who independently evaluated the required data. If no discrepancies were noted between the two reviewers, the chairman/co-chairman of the CEC then verified and approved the final adjudication. If discrepancies existed between the two reviewers, the two reviewers either resolved any discrepancy between them or were assisted in reconciling their assessments by the chairman/co-chairman. All members received a fixed remuneration regardless of their findings.
Criteria for blinded review were predetermined by the CEC before adjudication began and were based on variables commonly evaluated in previous sepsis trials (1, 3, 11) . The CEC adjudicated a) fulfillment of amended enrollment criteria (as detailed previously); b) significant underlying disorder; c) infection status (Appendix 2); d) primary site of infection; e) causative organism; f) adequacy of anti-infective therapy (Appendix 3) within 48 hrs of fulfilling criteria for diagnosis of infection; g) extent of life support measures; and h) patient outcome and cause of death.
The CEC defined a significant underlying disorder as the presence of an acute or chronic disease (excluding sepsis) that had a significant chance of causing death within the next 12 months or a severe underlying disorder that might increase the chances of a decision to forgo life-sustaining treatments (11) . The following underlying disorder categories were available for this classification: malignancy, neurologic, gastrointestinal, cardiac, pulmonary, status-postcardiac arrest, profound immunosuppression, and other.
We determined the primary sites of infection as lung, urinary tract, gynecologic, intraabdominal, indwelling catheter, skin or skin structure, central nervous system, cardiac, bone/joint, head/ears/nose/throat, pleural, other, unknown, and no evidence of focal infection.
We reviewed all of the culture data and determined if the causative organisms isolated from either the blood or the primary focus on infection had been correctly identified. The CEC assessed the extent of life support measures by determining whether a decision to forgo life-sustaining therapy during the 28-day study had been made. Removal of ventilatory or vasopressor support, a notation that the patient was given "comfort measures only," a decision by the family to withdraw care, or a decision to place the patient in "hospice care" all were considered as decisions to forgo life-sustaining therapy. A decision to withhold only cardiopulmonary resuscitation was not recorded as forgoing life-sustaining therapy. If no mention of a decision to forgo therapies was made, the patient was considered to have had full support.
We determined patient outcome and cause of death based on one of the following classifications: a) alive at day 28; b) died of causes unequivocally not related to sepsis and unequivocally not from an organ failure resulting from sepsis (nonseptic death); or c) died from sepsis or complications from sepsis (septic death).
Optimal Cohort Definition. The CEC evaluations determined the appropriately enrolled and treated subset of patients, or optimal cohort, in the PROWESS trial. We defined patients as part of the optimal cohort if they met all of the following criteria: a) patient was evaluable (enrolled patients receiving study drug for any length of time); b) patient met modified systemic inflammatory response syndrome and organ failure criteria without meeting an exclusion criterion and patient began drug therapy within 24 hrs of meeting inclusion criteria; c) patient had a definite or possible focal infection; and d) adequate antiinfective therapy had been administered.
Severity of Illness at Baseline and Biomarker Determinations. Acute Physiology and Chronic Health Evaluation (APACHE) II scores, (12) number and type of organ dysfunction, baseline mechanical ventilation status, baseline shock status, and markers of coagulopathy (protein C and D-dimer) and inflammation (interleukin-6) measured during PROWESS (10) were used to evaluate baseline disease severity and pharmacodynamic effects of drotrecogin alfa (activated) in the CEC-defined subgroups. These values were not evaluated by the CEC as part of the predetermined analysis plan.
Statistical Analyses. Pearson's chi-square test was used for analyses involving categorical data comparisons (e.g., mechanical ventilation usage). Analysis of variance was used for analyses involving continuous data comparisons (e.g., APACHE II scores). Biomarkers (e.g., D-dimer) were evaluated using ranked analysis of variance with the last observation carried forward imputation method for missing data. All comparisons were analyzed using two-sided 5% significance levels.
Observed 28-day mortality rates for drotrecogin alfa (activated) and placebo patients were reported for various subgroups. A subgroup result was reported to be consistent with the benefit observed in the overall trial if the subgroup 95% confidence interval for the relative risk contained the overall relative risk point estimate of 0.806 observed for the entire population. Relative risk and 95% confidence intervals were calculated using the logitadjusted method (13) .
RESULTS
Optimal Cohort. There were 1,375 patients (81.4%) in the ITT population [drotrecogin alfa (activated), n ϭ 695; placebo, n ϭ 680] who met the definition for the optimal cohort (Table 1) . Under the original version of the protocol, 720 patients were enrolled and received study drug compared with 970 patients enrolled under the amended protocol. The percentage of patients considered part of the optimal cohort enrolled under the original protocol vs. the amended protocol was similar (79.9%, n ϭ 575 vs. 82.5%, n ϭ 800, p ϭ .17).
In all, 315 patients [drotrecogin alfa (activated), n ϭ 155; placebo, n ϭ 160] were removed from the optimal cohort based on violation of an inclusion or exclusion criteria or inadequate antiinfective therapy and were analyzed separately. A patient may have met one or more of the criteria for removal from the optimal cohort. The most frequent violation of study protocol inclusion/exclusion criteria was the time window that corresponded to the beginning of treatment within 24 hrs after meeting the inclusion criteria [drotrecogin alfa (activated), n ϭ 55; placebo, n ϭ 48]. Other reasons for violation of exclusion criteria were increased risk of bleeding (n ϭ 8); patient was receiving an excluded medication (n ϭ 2); patient had esophageal varices, chronic jaundice, cirrhosis, or chronic ascites (n ϭ 2); patient had received a bone marrow, lung, liver, pancreatic, or small bowel transplant; or the patient's first sepsis-induced organ dysfunction was present for Ͼ24 hrs before the 24-hr period available to start the study drug. No statistically significant differences were observed between treatment groups with regard to satisfying protocol inclusion/exclusion criteria. As reported previously, the majority of the ITT patients (n ϭ 1,542, 91.2%) received adequate antiinfective therapy within 48 hrs of diagnosis of infection (10), and 89.2% of patients received adequate anti-infective therapy in Ͻ24 hrs of diagnosis of infection (Table 2) . No statistically significant difference was noted between treatment groups with regard to adequacy of antiinfective therapy.
Severity of illness at baseline (Table 3) , as measured by APACHE II scores, number and type of organ dysfunction, mechanical ventilation status, and shock status in the optimal cohort, was nearly identical to the overall ITT population as described in part previously by Bernard et al. (10) . With the exception of mechanical ventilation status [drotrecogin alfa (activated), 28.5%; placebo, 23.8%; p ϭ .049], there were no statistically significant differences between treatment groups in the optimal cohort. The patients excluded from the optimal cohort had significantly more disease severity at baseline as indicated by an increased number of organ dysfunctions and need for ventilation support. This group of patients also had significantly more hematologic and metabolic organ dysfunctions. Significantly more patients with underlying disorders were found in the group removed from the optimal cohort.
Biomarkers of coagulopathy and inflammation (protein C, D-dimer, and interleukin-6), both median baseline levels and changes over time ( Fig. 1) , were also very similar to results in the ITT population. Median protein C levels increased ITT, intention-to-treat; pts, patients; SIRS, systemic inflammatory response syndrome. b A patient may have met multiple criteria for exclusion from the optimal cohort. steadily over time in both drotrecogin alfa (activated) and placebo groups. The drotrecogin alfa (activated) group had higher median protein C levels at days 1 through 5, lower median D-dimer levels at days 1 through 6, and larger decreases in interleukin-6 levels on day 1 (223 vs. 161 pg/mL, p ϭ .024) than the placebo group of the optimal cohort population, as was observed in the ITT population (14) . The relative risk of death observed in both the optimal cohort and in the patient group that was not part of the optimal cohort was consistent with that observed in the overall trial (Fig. 2) .
Patients Receiving Inadequate AntiInfective Therapy. As previously reported, 148 patients (8.8%) in the ITT population [drotrecogin alfa (activated), n ϭ 74; placebo, n ϭ 74] received inadequate antiinfective therapy (10) . The severity of illness of these patients was similar to those receiving adequate anti-infective therapy as measured by mean APACHE II (25.3 vs. 24.7, p ϭ .39) and mean organ dysfunctions (2.5 vs. 2.4, p ϭ .15). A significantly higher percentage of patients with inadequate anti-infective therapy were on mechanical ventilation (85.1% vs. 74.5%, p ϭ .004). This patient group with inadequate anti-infective therapy had significantly higher nosocomial infections, more fungal and mixed infections, and more underlying disorders (all p Ͻ .001).
The observed mortality rates for drotrecogin alfa (activated) and placebo patients not receiving adequate antiinfective therapy (29.7% and 43.2%) were higher than the observed mortality rates for drotrecogin alfa (activated) and placebo patients receiving adequate antiinfective therapy (24.2% and 29.6%). The relative risk of mortality associated with drotrecogin alfa (activated) (Fig. 2) was consistent with the overall trial regardless of adequacy of anti-infective therapy.
CEC Evaluation of Microbiological Data. The treatment benefit by site of infection analyzed by the CEC was consistent with the original investigator determinations in PROWESS (Fig. 2) with the exception of urinary tract infections. The CEC adjudicated more urinary tract infection concomitant to another focus on infection, such as pneumonia or peritonitis. In the urinary tract infection subgroup, a clearer benefit associated with drotrecogin alfa (activated) treatment was observed compared with that based on investigator determinations. There was no significant difference in baseline disease severity, as measured by APACHE II scores, between the group of urinary tract infections based on investigator determinations (25.9 Ϯ 8.8) compared with urinary tract infections adjudicated by the CEC (26.2 Ϯ 8.6).
The most prevalent Gram-positive cocci identified by the CEC were S. aureus and S. pneumoniae, whereas E. coli was the most prevalent Gram-negative bacteria in the two treatment groups (Table 4). The number of coagulase negative staphylococci as causative organism markedly decreased after the CEC reviewing process in both groups. The number of patients with Enterococcus sp and Bacterioides sp identified as the causative organism by the CEC increased. The CEC took into account all of the microorganisms isolated in the peritoneal cavity.
Patients With Significant Underlying Disorder. There were 296 patients (17.5%) in the ITT population [drotrecogin alfa (activated), n ϭ 131; placebo, n ϭ 165; p ϭ .02] who met the CEC definition of a significant underlying disorder at study entry. Of the 720 patients enrolled under the original protocol, 139 patients (19.3%) had a significant underlying disorder compared with 157 patients (16.2%) of 970 patients enrolled under the amended protocol (p ϭ .095). Patients with underlying disorders had significantly more baseline cardiovascular organ dysfunction (77.0% vs. 70.3%, p ϭ .029), were more frequently on mechanical ventilation (80.1% vs. 74.5%, p ϭ .042), and had higher mean baseline APACHE II scores (27.1 vs. 24.3, p Ͻ .0001) compared with those without significant underlying disorder. These patients also tended to have more shock at baseline than patients without underlying disorder. The APACHE II difference in patients with and without underlying disorder was related to the mean chronic health disease score (2.6 vs. 0.6) and mean age score (4.2 vs. 3.3) (p Ͻ .001), whereas the mean acute physiology score was similar (20.3 vs. 20.4) . The mean number of entry organ dysfunctions was Median baseline levels of protein C (53.0% vs. 47.0%; p ϭ .005) were higher, and median D-dimer (3.8 vs. 4.2 g/mL, p ϭ .027) and median interleukin-6 (339 vs. 533 pg/mL, p ϭ .0002) levels were lower in patients with underlying disorder compared with those without underlying disorder. The effects over time of drotrecogin alfa (activated) on biomarkers were similar to those observed in the ITT group regardless of underlying disorder (data not shown).
The observed mortality rates for drotrecogin alfa (activated) and placebo patients with significant underlying disorder (40.5% and 55.8%) were higher than the observed mortality rates for the drotrecogin alfa (activated) and placebo groups without underlying disorder (21.8% and 24.7%). Regardless of the presence of an underlying disorder, the survival benefit associated with drotrecogin alfa (activated) was consistent with that observed in the overall ITT population (Fig. 2) .
Analyses of Life Support Measures and Causes of Death.
Of the 469 patients who died in the study, 250 patients [drotrecogin alfa (activated), n ϭ 107, 42.8%; placebo, n ϭ 143, 57.2%] were classified as forgoing life-sustaining therapy. In the group forgoing life-sustaining therapy, the mean time from the start of study drug infusion to the decision to forgo life-sustaining therapy [drotrecogin alfa (activated), 7.5 days; placebo 8.0 days], the time between forgoing life-sustaining therapy and death [drotrecogin alfa (activated), 1.7 days; placebo, 2.0 days], and the observed mortality rates [drotrecogin alfa (activated), 94.4%; placebo, 96.5%] were similar in the two treatment groups. Less than 1% of patients in either treatment group surviving at 28 days had forgone life-sustaining therapy. There was a significantly higher percentage of patients recorded as forgoing life-sustaining therapy in the subgroup with significant underlying disorder than in the group without significant underlying disorder (31.4% vs. 11.3%, p Ͻ .0001).
Of the 469 total deaths in the ITT population (drotrecogin alfa (activated), n ϭ 210; placebo, n ϭ 259), 74 deaths (15.8%) were nonseptic related. There were 38 (5.3%) nonseptic deaths in the patients enrolled under the original protocol (n ϭ 720) compared with 36 (3.7%) nonseptic deaths in the patients enrolled under the amended protocol. There were 28 nonseptic-related deaths (13.3%) in the drotrecogin alfa (activated) group and 46 nonseptic-related deaths (17.8%) in the placebo group (p ϭ .19). Of those patients who died of a nonseptic-related cause in each treatment group, the presence of significant underlying disorder [drotrecogin alfa (activated), n ϭ 17, 60.7%; placebo, n ϭ 25, 54.4%] and the percentage of patients forgoing lifesustaining treatment [drotrecogin alfa (activated), n ϭ 18, 64.3%; placebo, n ϭ 25, 54.4%] were similar. If all nonseptic deaths were removed from the ITT population, a survival benefit consistent with the overall trial was observed (0.82, 95% confidence interval 0.69 -0.98). 
DISCUSSION
The present study from the CEC of the PROWESS trial is the first to evaluate the optimal cohort in terms of severity of illness, relative risk of death, and pharmacodynamic effect of the study drug in a successful trial in severe sepsis patients. More than 80% of the ITT population comprised the optimal cohort, defined as patients who had full compliance with the protocol, had evidence of an infection, and received adequate anti-infective therapy. Not surprisingly, based on the size of the optimal cohort, the relative risk of death in the optimal cohort was consistent with that observed in the overall trial as were the time courses for markers of coagulation and inflammation. Patients removed from the optimal cohort were more severely ill as measured by number of baseline organ dysfunctions and need for mechanical ventilation, and they had significantly more underlying disorders. The group of patients removed from the optimal cohort based on CEC analyses, including patients receiving inadequate anti-infective therapy and those who were more severely ill with underlying disorders, still showed a treatment benefit with drotrecogin alfa (activated).
Introduction of a protocol amendment during the PROWESS trial had essentially no effect on the number of patients removed from the optimal cohort. This implies that the amendment did not substantially change the population of patients enrolled in PROWESS. The percentage of significant underlying disorders and nonseptic deaths in patients enrolled under the amended protocol was smaller compared with patients enrolled under the original protocol. This was an expected outcome of the clarification of entry criteria put in place to increase enrollment of patients with acute infectious illness and not severe underlying diseases.
Several recent sepsis clinical trials (6, 7, 9, 15) of coagulation and inflammatory cascade inhibitors aimed at improving mortality used a CEC to classify patients. These assessments have included the clarification of underlying disease, microbiological data, the primary site of infection, the adequacy of anti-infective therapy and surgical management, the extent of life-support measures, and cause of death. The methods used in assessing the patients in the PROWESS trial are similar to those described by Sprung et al. (1), except for the definition of the "valid" or "optimal" cohort, especially with regard to the removal of patients with confounding events. Sprung et al. (1) defined a confounding event as an event that objectively interfered with the potential for the investigational intervention to exercise its effect, including inappropriate anti-infective therapy, inadequate medicalsurgical management, or an underlying condition that was likely to have a direct impact on survival at 28 days. The CEC of the PROWESS trial decided that inappropriate anti-infective therapy would be the only confounding event that could be objectively assessed in the trial because clear data were reported by investigators in the case report forms regarding the focus on infection and isolated microorganisms. In addition, criteria are well defined and accepted to assess adequacy of anti-infective therapy (16, 17) . The objective assessment of other medical management by a CEC is much more difficult (and subjective), because no rules are universally accepted in all countries and precise data about this management were usually not available in the CRFs. A surgical review of PROWESS patients is ongoing.
The characteristics of the optimal cohort confirm the quality of the data collected, as well as the consistency of the beneficial effect of drotrecogin alfa (acti- Figure 2 . Twenty-eight-day all-cause mortality across subgroups defined as part of optimal cohort, adequacy of anti-infective therapy, and presence of significant associated life-threatening disorder. The point estimate of relative risk of death in each subgroup is indicated by a solid round symbol and the 95% confidence interval (CI) by the horizontal lines. The intention-to-treat (ITT) group refers to the relative risk and 95% CI, with accompanying mortality rates, for the overall trial population; N, total number of patients in the subgroup; TRT, drotrecogin alfa (activated) group; PLC, placebo group; RR, relative risk of death; INV, investigator determined site of infection; CEC, Clinical Evaluation Committee determined site of infection. vated) in the PROWESS trial. Despite the differences in defining the optimal cohort, it is possible to compare the percentage of protocol violations across trials. The percentage of protocol violations was the lowest for PROWESS: 9.9% of the ITT population of PROWESS vs. 14% in the INTERSEPT trial (1) and 10% in the PAFra trial (8) . The most frequent protocol violation in PROWESS was related to the beginning of treatment within 24 hrs after meeting the inclusion criteria. The adequacy of anti-infective therapy in PROWESS is similar to other trials despite a more restrictive definition (Appendix 3): 91.2% of the PROWESS population vs. 95% and 93.5% in the INTERSEPT trial (1) and PAFra trials, (8) respectively. If our definition of the optimal cohort was applied to other trials, the percentage of patients maintained in the optimal cohort was similar: 81.4% vs. 81.4% in the INTERSEPT trial (1) and 80% in the PAFra trial (8) .
This is the first study to provide an extensive definition of infection status and adequacy of antimicrobial therapy. The definitions provided here (Appendixes 2 and 3) can be useful for future studies. This is also the first study to analyze the population who did not receive adequate anti-infective therapy in a large sepsis trial. These patients had higher placebo mortality rate, potentially related to the inappropriate therapy against the organism responsible for their infection, but it is interesting to note that they were more severely ill at baseline. This severity of illness may account for increased nosocomial, mixed, and fungal infections in this subgroup, leading to a more difficult choice of initial anti-infective therapy, especially given the presence of antibiotic-resistant bacteria. The results of our study were consistent with those of Kollef and coworkers (18), who prospectively evaluated the relationship between inadequate anti-infective therapy and hospital mortality rate in critically ill patients. They reported that inadequate anti-infective therapy was the most important independent determinant of hospital mortality in critically ill patients. They also found that patients who received inadequate antiinfective therapy were more severely ill and had higher infection-related mortality rate than patients with adequate antiinfective therapy (42 vs. 18%, p Ͻ .001).
A full and integrated review of microbiological data by the CEC, although mostly consistent with the original investigator determinations, led to some changes in the primary focus on infection and the causative organisms as well. In contrast with the original investigator determinations, we observed a benefit associated with drotrecogin alfa (activated) treatment in the urinary tract infection group consistent with that observed in intra-abdominal and lung infections and the overall PROWESS trial. This is most likely due to the fact that the CEC adjudicated more concomitant sites of infection (urinary tract infection associated with intra-abdominal, lung, or other sites of infection) than the investigators. In addition, the number of coagulase negative staphylococci as the causative organism markedly decreased after the CEC reviewing process in the two groups, because of the strict CEC definition of this infection. The higher number of Enterococcus sp and Bacteroides sp in the CEC analysis is related to the fact that the CEC took into account all of the microorganisms isolated in the peritoneum in patients with peritonitis.
The number of patients with underlying disorder in PROWESS was slightly higher than that reported in the HA-1A trial (11) (18% vs. 12%). The severity of the illness of patients in PROWESS with underlying disorder was related both to their chronic health status and age and to the septic episode, as suggested by the analyses of the component parts of the APACHE II score and their lesser coagulation and inflammatory response. Despite this reduced response to infection and severity of disease, the relative risk in this subgroup still favored drotrecogin alfa (activated). The benefit observed in patients with underlying disorder may be the explanation for the absence of a greater beneficial effect of drotrecogin alfa (activated) in the PROWESS optimal cohort compared with the ITT group, in contrast to the effect reported in the IN-TERSEPT trial (1) . A significantly lower percentage of patients with severe underlying conditions that may have had a direct positive impact on survival at 28 days was retained in the optimal cohort in PROWESS compared with the group excluded from the optimal cohort (Table 3) . This also suggests that serious underlying disorder should not, in general, be a reason for contraindicating drotrecogin alfa (activated) in such patients. Forgoing of life-sustaining treatment occurred less frequently in PROWESS than in the HA-1A trial (11): 15% vs. 22%. This is likely related in part to the positive outcome of the PROWESS trial and possible reluctance to forgo lifesustaining treatment as patients improved. The time between the start of the study drug infusion and the forgoing lifesustaining treatment (7.8 vs. 7.6 days) and the time between forgoing lifesustaining treatment and death (1.9 vs. 2.8 days) were similar in the two studies, as well as the mortality rate (28-day mortality rate of 95% vs. hospital mortality rate of 94%).
In PROWESS, the slightly higher number of those forgoing life-sustaining therapy (143 vs. 107) observed in the placebo group compared with the treated group essentially was related to the higher number of deaths in the placebo group (259 vs. 220). As might be expected, a higher percentage of patients with underlying disorder had forgone life-sustaining therapy than in those patients without underlying disorder. Although the nonseptic deaths tended to be higher in the placebo group (46 vs. 28, p ϭ .19), this result was not statistically significant. Even when the nonsepticrelated deaths were removed from the ITT population, a consistent treatment benefit of drotrecogin alfa (activated) was still observed.
Several limitations of this study should be noted. Clinical trials, such as PROWESS, typically are powered to detect an overall effect and are thus underpowered to make strong inferences about particular subgroups. In addition, the PROWESS trial was stopped early due to overwhelming efficacy, thereby further limiting the statistical power (19 -21) . Analyses of subgroup results from a clinical trial may be misleading due to a combination of reduced statistical power, increased variance, multiplicity, and the play of chance (22) and, therefore, should be viewed as exploratory and hypothesis generating. Although the multinational, multiple-site nature of the trial could have enhanced variability in the trial, a block-of-4 randomization schedule (to which investigators were blinded) minimizes these effects between treatment groups. We also were unable to objectively remove patients with an underlying or unforeseen condition that may have had a direct impact on survival at 28 days. However, because patients not expected to survive given a preexisting medical condition and patients with advance directive prohibiting life support were excluded from this trial, the decision from the investigator and/or patient's family to forgo lifesaving treatment of the patient may have occurred later when aggressive management had failed. Although, it is clearly not the case in most of the patients, it is impossible to determine how many patients in this study, in whom therapy was forgone, would have lived had aggressive treatment been continued. It is reasonable, however, to assume that a small number would have lived, especially among those who survived to the 28th day (Ͻ1%) despite the decision to forgo treatments. Objective assessment of the impact of the last two confounding events on mortality rate will remain very difficult, despite extensive information about the patient's condition. Finally, one potential source of bias in the CEC evaluation of the PROWESS data is that the members of the CEC were also participants in the PROWESS study. This bias is minimized by the fact that reviewers were blinded to patient allocation, did not adjudicate CRFs from patients from their own study site, and received a fixed remuneration regardless of their findings.
CONCLUSIONS
This study supports the value of a CEC even in a positive trial and offers suggestions for the role of CECs in future sepsis trials in not only assessing the extent of protocol violations but also clarifying underlying disease and microbiological data and identifying the primary site of infection, the impact of confounding events, causes of death, and the adequacy of medical and surgical management, tasks that are not easily computerized. Although not assessed by the PROWESS CEC, it will be important to assess the medical and surgical management of patients with severe sepsis in future trials and to have the ability to objectively compare the actual management with widely recognized guidelines. These guidelines should take into account recent and major insights concerning the hemodynamic management (23) , intensive insulin therapy (24) , and daily hemodialysis (25) or continuous hemofiltration (26) .
Even in a well-designed and executed trial such as PROWESS, patients were inadvertently enrolled who did not satisfy all inclusion and exclusion criteria. The role of the CEC in the successful PROW-ESS trial in severe sepsis patients was to define and evaluate the optimal cohort, verify the microbiological data, assess adequacy of antibiotics, analyze patients with underlying disorders, and evaluate life support measures and causes of death. The critical review of data by the CEC confirms that the results observed in the ITT group of PROWESS (10) are similar in the optimal cohort of appropriately enrolled and adequately treated patients. Analyses by the CEC also provided important additional information not included in the original PROWESS publication (10) especially regarding patients with adequate antiinfective therapy, those with urinary tract infections, and those with significant underlying disorders. The CEC analysis confirms that severely ill septic patients, especially those with underlying disorders, appear to benefit more from treatment. Both U.S. and European regulatory authorities have now approved drotrecogin alfa (activated) for treatment of adult patients with severe sepsis at high risk of death as assessed by, for example, high APACHE II score in the United States or adult severe Inclusion criteria To be eligible for enrollment in this study, patients must have a suspected or proven infection, evidence of systemic inflammation, and at least one sepsis-induced organ failure.
Clarification for sepsis-induced organ failure added. Patients who have pre-existing, non-sepsis-induced organ failures also may participate in this study. However, the non-sepsis-induced organ failure may not be used to qualify the patient for entry into the study even if the organ failure were to worsen as a result of the septic episode. In this instance, the patient must develop a new organ failure, which is sepsis-induced, to be eligible for participation in this study. Criteria for suspected infection added. Suspected or proven infection.
Patients with suspected infection must have evidence of an infection such as white blood cells in a normally sterile body fluid, perforated viscus, chest radiograph consistent with pneumonia and associated with purulent sputum production, or a clinical syndrome associated with a high probability of infection (e.g., ascending cholangitis). Respiratory: PaO 2 /FIO 2 Յ250; if the lung is the sole organ meeting criteria, as well as the suspected site of infection, the patient must have a PaO 2 /FIO) Յ200. PaO 2 /FIO 2 ratio must be based on arterial blood gas results.
APPENDIX 1 (continued)
Hematology: Platelet count Ͻ80,000/mm 3 or a 50% decrease in the platelet count from the highest value recorded over the last 3 days.
No change. Patients with end-stage liver disease as evidenced by esophageal varices, chronic jaundice, cirrhosis, or chronic ascites. Patients not expected to survive given preexisting medical condition.
Patients not expected to survive given preexisting uncorrectable medical conditions. This would include patients with, or suspected to have, poorly controlled neoplasms or other end-stage processes (eg. endstage cardiac disease, prior cardiac arrest, end-stage lung disease, endstage live disease, etc.). Enrollment of patients with cancer required approval from coordinating center. Patients who are moribund and where death is imminent. Patients whose family or physician had not committed to aggressive management of the patient. Patients with bone marrow, lung, liver, pancreas, and small bowel transplantation. Patients at increased risk for bleeding, for example, history of severe head trauma that required hospitalization, intracranial surgery, or stroke within the previous 3 months, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion.
Patients at increased risk for bleeding, for example, history of severe head trauma that required hospitalization, intracranial surgery, or stroke within the previous 3 months, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion. Patients with an epidural catheter or who are anticipated to receive an epidural catheter during study drug infusion also are excluded from this study. Trauma patients at increased risk of bleeding (e.g., flail chest; significant contusion to lung, liver, or spleen; retroperitoneal bleed; pelvic fracture; compartment syndrome). Patients with a known hypercoagulable condition including activated protein C resistance, a hereditary deficiency of protein C, protein S, or antithrombin III.
Patients with a known hypercoagulable condition including activated protein C resistance; a hereditary deficiency of protein C, protein S, or antithrombin III; presence of anticardiolipin antibody; antiphospholipid syndrome; lupus anticoagulant; homocysteinemia; or patients with a recently documented (Ͻ3 months) or highly suspected deep venous thrombosis or pulmonary embolism.
